News

The Australian company had already worked with Lilly to prepare an advanced draft of the clinical study protocol before signing the significant agreement.

New Zealand's Pharmac says it is refreshing its patient advisory function to strengthen the way patient voices and lived experience inform its decisions.

The PBS is an outlier when it comes to patient rights. It is not just the NDIS. Contrast the non-existence of a patient charter of rights for PBS decision-making with hospitals and aged care. Even private health insurers are subject to an ombudsman with investigatory powers. What makes this program uniquely resistant to patient agency and rights?

Arrotex Pharmaceuticals, Australia's largest locally-owned pharmaceutical company, has announced the appointment of Dr Melinda Munns as Chief Medical Officer.

The pricing outcomes negotiated in these agreements will likely have a far bigger impact on access outcomes than anything implemented as a result of the Health Technology Assessment Review.

Widespread reports of a potential merger between AstraZeneca and Bristol Myers Squibb that would bring together two of the pharmaceutical industry’s most influential oncology businesses.

The classic story is a family sitting at home. Someone suggests driving to dinner. Nobody really wants to go, but each person thinks the others do, so everyone agrees. After an exhausting trip, they discover that everyone would have preferred to stay home. Sound familiar?

Mélanie Chamaux, General Manager of Servier Australia and New Zealand, described the listing as the result of a collective effort involving

Simon Dawson, General Manager, Kyowa Kirin Australia and Head of the APAC Cluster covering Australia, Korea and Taiwan, said the listing would provide an important option for eligible patients.

“As the first new therapy to be reimbursed on the PBS for R/R FL in nine years, we are extremely proud to have partnered with Incyte to bring Minjuvi to Australia,” said Carlo Montagner, ST Chief Executive Officer.

The events in the US this week surrounding a former public health leader raise some important questions in Australia about the accountability of 'independent experts'. Why we can't afford to muck up the AI opportunity as new evidence on its use emerges globally. Ongoing debate over access to medicines and the impact of global pricing.

A unique three‑way collaboration announced in Sydney seeks to build a practical blueprint for how Australia can confront a growing dementia crisis, with a particular focus on Alzheimer’s disease.